Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Type 1 Diabetes in Acute Pancreatitis Consortium
- PMID: 36206464
- PMCID: PMC9555853
- DOI: 10.1097/MPA.0000000000002077
Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Type 1 Diabetes in Acute Pancreatitis Consortium
Abstract
Differences in methods for biospecimen collection, processing, and storage can yield considerable variability and error. Therefore, best practices for standard operating procedures are critical for successful discovery, development, and validation of disease biomarkers. Here, we describe standard operating procedures developed for biospecimen collection during the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study within the Type 1 Diabetes in Acute Pancreatitis Consortium. Notably, these protocols were developed using an integrative process based on prior consortium experience and with input from working groups with expertise in immunology, pancreatitis, and diabetes. Publication and adoption consistent biospecimen protocols will inform future studies and allow for better comparisons across different metabolic research efforts.
Copyright © 2022 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Conflict of interest statement
D.K.A. is part of advisory board for National Pancreas Foundation and American Pancreatic, Association Foundation and receives royalties from McGraw-Hill. M.D.B receives research support from Viacyte and Dexcom and is part of advisory board for Insulet. P.J.L. is part of advisory board for AbbVie. R.E.P. has consulting activities with Bayer AG, Corcept Therapeutics Incorporated, Dexcom, Gasherbrum Bio, Inc, Hanmi Pharmaceutical Co, Hengrui (USA) Ltd, Merck, Novo Nordisk, Pfizer, Rivus, Pharmaceuticals, Inc, Sanofi, Scohia Pharma, Inc, and Sun Pharmaceutical Industries; receives research support from Hanmi Pharmaceutical Co, Janssen, Metavention, Novo Nordisk, Poxel, SA, and Sanofi; and receives speaking fees from Novo Nordisk. E.K.S. receives speaking fees from MedScape. C.S. is part of advisory board for Vertex Pharmaceuticals. The other authors declare no conflict of interest.
Figures
References
-
- Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119:92–101. - PubMed
-
- Biorepositories and Biospecimen Research Branch. NCI Best Practices for Biospecimen Resources. Bethesda, MD; National Cancer Institute, National Institutes of Health: 2016. Available at: https://biospecimens.cancer.gov/bestpractices/. Accessed April 2022.
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK127403/DK/NIDDK NIH HHS/United States
- R21 DK122293/DK/NIDDK NIH HHS/United States
- U01 DK127392/DK/NIDDK NIH HHS/United States
- U01 DK127395/DK/NIDDK NIH HHS/United States
- U01 DK127388/DK/NIDDK NIH HHS/United States
- U01 DK127377/DK/NIDDK NIH HHS/United States
- KL2 TR002002/TR/NCATS NIH HHS/United States
- R01 DK123329/DK/NIDDK NIH HHS/United States
- K01 DK120737/DK/NIDDK NIH HHS/United States
- U01 DK127367/DK/NIDDK NIH HHS/United States
- U01 DK127382/DK/NIDDK NIH HHS/United States
- U01 DK127400/DK/NIDDK NIH HHS/United States
- P30 DK097512/DK/NIDDK NIH HHS/United States
- U01 DK127378/DK/NIDDK NIH HHS/United States
- U01 DK127404/DK/NIDDK NIH HHS/United States
- U01 DK127384/DK/NIDDK NIH HHS/United States